CompletedPhase 2NCT05152173
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Studying Ledderhose disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Endo Pharmaceuticals
- Principal Investigator
- Luis Ortega, MDEndo Pharmaceuticals
- Intervention
- EN3835(biological)
- Enrollment
- 176 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (30)
- Endo Clinical Trial Site #29, Mesa, Arizona, United States
- Endo Clinical Trial Site #42, Tucson, Arizona, United States
- Endo Clinical Trial Site #15, Bakersfield, California, United States
- Endo Clinical Trial Site #41, Encinitas, California, United States
- Endo Clinical Trial Site #9, Fresno, California, United States
- Endo Clinical Trial Site #27, La Mesa, California, United States
- Endo Clinical Trial Site #30, Los Angeles, California, United States
- Endo Clinical Trial Site #12, Tarzana, California, United States
- Endo Clinical Trial Site #36, Torrance, California, United States
- Endo Clinical Trial Site #22, Vista, California, United States
- Endo Clinical Trial Site #13, Whittier, California, United States
- Endo Clinical Trial Site #16, Atlantis, Florida, United States
- Endo Clinical Trial Site #43, Jacksonville, Florida, United States
- Endo Clinical Trial Site #40, Miami, Florida, United States
- Endo Clinical Trial Site #10, Pinellas Park, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05152173 on ClinicalTrials.govOther trials for Ledderhose disease
Additional recruiting or active studies for the same condition.